<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/167BFEC6-2898-4B8F-8D91-DC3426A965D5"><gtr:id>167BFEC6-2898-4B8F-8D91-DC3426A965D5</gtr:id><gtr:firstName>Mary</gtr:firstName><gtr:otherNames>Anne</gtr:otherNames><gtr:surname>O'Connell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_U127584490"><gtr:id>6A3FC5AB-B2F2-49C4-982C-D4145B4E628F</gtr:id><gtr:title>Elucidating the biological roles, regulation and specificities of the ADAR and APOBEC editing enzymes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_U127584490</gtr:grantReference><gtr:abstractText>The cytidine deaminases (CDA) are a large family of enzymes that can deaminate nucleic acids and thereby change the encoded base. Members of this family include ADARs (adenosine deaminases that act on RNA) and APOBEC that edit both DNA and RNA. The ADARs convert specific adenosines to inosines that are read as if they were guanosine by the translational machinery. Therefore if editing occurs within an exon it can result in another amino acid being inserted at the edited position. Most of the transcripts that are edited within exons are expressed in the CNS, so editing can have a major consequence on the property of the encoded protein and on the functioning of the nervous system.||One of the aims of my group is to determine what regulates the specificity of the ADAR enzymes. If it were not for this specificity, additional adenosines would be edited which would have detrimental consequences on the cell. To study this question we use Drosophila as a model system. We have strains of flies where the Adar gene is deleted and we can rescue the mutant phenotype by generating humanised flies where we have insert different human ADAR genes into Drosophila. By this method we can dissect the substrate preference for the different ADAR proteins. One interesting result from this study is that ADAR1 does not appear to be a bone fide editing enzyme despite having deaminase activity. So the question arises is it involved in the innate immune response like the APOBEC enzymes and does it play a role in RNA interference?||The Adar null flies have problems with locomotion and suffer from ataxia. They also experience age related neurodegeneration with large vacuoles in the central complex of their brain as well as degeneration of the retina. To study this neurodegeneration, we first have to classify what type of neurodegeneration it is. We also want to determine which human disorder is it most closely related to and so gain insights into this disorder. In addition, we are attempting to rescue the locomotion and neurodegeneration phenotype by making transgenic flies expressing the edited isoform of one of our candidate edited transcripts. Preliminary results suggest that it is easier to rescue neurodegeneration than locomotion.||Finally we want to broaden our research and study APOBEC enzymes that edit both RNA and DNA. As these enzymes are closely related to the ADARs we can use the same biochemical methods we use with ADARs.</gtr:abstractText><gtr:technicalSummary>The cytidine deaminases (CDA) are a large family of enzymes that can deaminate nucleic acids and thereby change the encoded base. Members of this family include ADARs (adenosine deaminases that act on RNA) and APOBEC that edit both DNA and RNA. The ADARs convert specific adenosines to inosines that are read as if they were guanosine by the translational machinery. Therefore if editing occurs within an exon it can result in another amino acid being inserted at the edited position. Most of the transcripts that are edited within exons are expressed in the CNS, so editing can have a major consequence on the property of the encoded protein and on the functioning of the nervous system.||One of the aims of my group is to determine what regulates the specificity of the ADAR enzymes. If it were not for this specificity, additional adenosines would be edited which would have detrimental consequences on the cell. To study this question we use Drosophila as a model system. We have strains of flies where the Adar gene is deleted and we can rescue the mutant phenotype by generating humanised flies where we have insert different human ADAR genes into Drosophila. By this method we can dissect the substrate preference for the different ADAR proteins. One interesting result from this study is that ADAR1 does not appear to be a bone fide editing enzyme despite having deaminase activity. So the question arises is it involved in the innate immune response like the APOBEC enzymes and does it play a role in RNA interference?||The Adar null flies have problems with locomotion and suffer from ataxia. They also experience age related neurodegeneration with large vacuoles in the central complex of their brain as well as degeneration of the retina. To study this neurodegeneration, we first have to classify what type of neurodegeneration it is. We also want to determine which human disorder is it most closely related to and so gain insights into this disorder. In addition, we are attempting to rescue the locomotion and neurodegeneration phenotype by making transgenic flies expressing the edited isoform of one of our candidate edited transcripts. Preliminary results suggest that it is easier to rescue neurodegeneration than locomotion.||Finally we want to broaden our research and study APOBEC enzymes that edit both RNA and DNA. As these enzymes are closely related to the ADARs we can use the same biochemical methods we use with ADARs.</gtr:technicalSummary><gtr:fund><gtr:end>2013-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>710053</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9C442BDA-229B-4A55-A658-11C870EA64DC</gtr:id><gtr:title>Solution structure of the N-terminal dsRBD of Drosophila ADAR and interaction studies with RNA.</gtr:title><gtr:parentPublicationTitle>Biochimie</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7078800f1c4f6672e925bdab166d109"><gtr:id>e7078800f1c4f6672e925bdab166d109</gtr:id><gtr:otherNames>Barraud P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-9084</gtr:issn><gtr:outcomeId>pm_14742_22_22210494</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA27F44E-BCF6-4AB5-BDF4-57AD08F25918</gtr:id><gtr:title>Mutations in ADAR1 cause Aicardi-Gouti&amp;egrave;res syndrome associated with a type I interferon signature.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f018c1451a2a6b8fcc0b72e90d951a01"><gtr:id>f018c1451a2a6b8fcc0b72e90d951a01</gtr:id><gtr:otherNames>Rice GI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>pm_14742_22_23001123</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_U127584490</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>